Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
NCT02684838 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 272
Last updated 2025-11-10
Summary
This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.
Conditions
- CNS Tumor
Sponsors & Collaborators
-
Arbor Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-04-26
- Primary Completion
- 2025-06-23
- Completion
- 2025-06-23
Countries
- United States
Study Locations
More Related Trials
-
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
NCT03460782 ·Status: NO_LONGER_AVAILABLE
-
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
NCT02300532 ·Status: COMPLETED
-
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00362921 ·Status: COMPLETED ·Phase: PHASE2
-
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT03422094 ·Status: TERMINATED ·Phase: PHASE1
-
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
NCT01400958 ·Status: TERMINATED ·Phase: PHASE2
-
Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
NCT00045721 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
NCT02586857 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
NCT00003467 ·Status: COMPLETED ·Phase: PHASE2
-
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
NCT00352313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
NCT00076986 ·Status: COMPLETED ·Phase: PHASE3
-
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
NCT06622434 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Navigating the Clinical Research Process for Glioma
NCT05958472 ·Status: NOT_YET_RECRUITING
-
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
NCT02279992 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients
NCT00576446 ·Status: COMPLETED ·Phase: PHASE1
-
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
NCT00814593 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT02924038 ·Status: TERMINATED ·Phase: PHASE1
-
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
NCT03493932 ·Status: COMPLETED ·Phase: PHASE1
-
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
NCT00003876 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
NCT00012038 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
GliaSite 1-3 Mets Study
NCT00589212 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
NCT04116411 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
NCT00093964 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
NCT01044225 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
NCT05484622 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
NCT00003463 ·Status: COMPLETED ·Phase: PHASE1